💊FDA Notices Regulatory Review Period for JAYPIRCA Patent Extension
Determination of Regulatory Review Period for Purposes of Patent Extension; JAYPIRCA
Summary
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JAYPIRCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$ - Med
The document concerns the regulatory review period for patent extension related to the human drug JAYPIRCA. This presents financial implications for businesses in the pharmaceutical industry, particularly those involved in patent applications and drug marketing, as it affects the duration of patent protection and potential profitability.